(0.15%) 5 316.07 points
(0.08%) 39 840 points
(0.13%) 16 816 points
(-0.63%) $79.30
(-2.40%) $2.69
(-0.60%) $2 423.90
(-0.93%) $32.13
(-0.10%) $1 062.60
(0.08%) $0.921
(-0.31%) $10.66
(-0.04%) $0.787
(-0.40%) $90.31
-6.28% $ 1.800
@ $0.657
Emitido: 14 feb 2024 @ 15:30
Retorno: 174.18%
Señal anterior: feb 14 - 09:30
Señal anterior:
Retorno: 6.16 %
Live Chart Being Loaded With Signals
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD...
Stats | |
---|---|
Volumen de hoy | 4.80M |
Volumen promedio | 9.47M |
Capitalización de mercado | 463.19M |
EPS | $0 ( 2024-05-14 ) |
Próxima fecha de ganancias | ( $-0.0600 ) 2024-08-19 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.83 |
ATR14 | $0.00800 (0.44%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-16 | Qamar Huma | Buy | 308 465 | Option (Right to Buy) |
2024-03-18 | Qamar Huma | Sell | 0 | Common Stock |
2023-09-15 | Breininger Michael | Buy | 0 | |
2024-01-03 | Musunuri Shankar | Sell | 180 204 | Common Stock |
2024-01-03 | Upadhyay Arun | Sell | 41 633 | Common Stock |
INSIDER POWER |
---|
65.74 |
Last 96 transactions |
Buy: 10 862 012 | Sell: 2 992 475 |
Volumen Correlación
Ocugen Inc Correlación
10 Correlaciones Más Positivas | |
---|---|
QNST | 0.939 |
PVAL | 0.937 |
LFMDP | 0.935 |
RNA | 0.935 |
GRID | 0.933 |
DWLD | 0.932 |
AVO | 0.93 |
SG | 0.928 |
QFIN | 0.927 |
SHLD | 0.926 |
10 Correlaciones Más Negativas | |
---|---|
UONEK | -0.918 |
RMGC | -0.904 |
PRTS | -0.902 |
TTEC | -0.902 |
ACAD | -0.9 |
UONE | -0.897 |
AGRX | -0.895 |
EEIQ | -0.895 |
NLSP | -0.893 |
QNRX | -0.892 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ocugen Inc Correlación - Moneda/Commodity
Ocugen Inc Finanzas
Annual | 2023 |
Ingresos: | $6.04M |
Beneficio Bruto: | $5.33M (88.34 %) |
EPS: | $-0.260 |
FY | 2023 |
Ingresos: | $6.04M |
Beneficio Bruto: | $5.33M (88.34 %) |
EPS: | $-0.260 |
FY | 2022 |
Ingresos: | $0 |
Beneficio Bruto: | $-1.07M (0.00 %) |
EPS: | $-0.360 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-0.300 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Ocugen Inc
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico